IRWD (Ironwood Pharma) Forward P/E Multiple

Corporate emblem and logo of ironwoodpharma.com (IRWD)

This chart illustrating the P/E ratio history for Ironwood Pharmaceuticals (IRWD) is 3.50. Ironwood Pharmaceuticals has reached business maturity, relying on the demand for Linzess as a profit generator. The company is recognized as an expert in gastroenterology, earning physician acclaim by developing effective medications that significantly transform the daily lives of a vast number of patients worldwide.

IRWD - Ironwood Pharmaceuticals, Inc. Market Cap to Projected Earnings over the range 07/04/2022 - 11/18/2026

Analytical breakdowns and data insights for company ironwoodpharma.com (IRWD)

- current price and projected stock value:
- business market valuation indicators:
Brand item of Ironwood Pharmaceuticals

Investors are evaluating Ironwood Pharmaceuticals (IRWD) through the lens of its specialized portfolio efficiency. This metric compares the current market value of the share with the projected net profit for the coming year. An analysis of the company's forward P/E NTM reveals the asset's undervaluation relative to expected cash flow. The stability of this indicator is supported by the absence of proprietary manufacturing risks due to the outsourcing of drug production. Low values of this indicator signal an increase in the investment's margin of safety.